TheraRadar
Data updated: May 26, 2026

DESMODA (desmopressin acetate)

Metabolic Approved 2026-02-25

DESMODA is indicated for the management of central diabetes insipidus as antidiuretic replacement therapy for adults and pediatric patients.

1
Indication
--
Phase 3 Trials
0
Years on Market

Details

Status
Prescription
First Approved
2026-02-25
Patent Cliff
2044

Pro Metrics

Patent cliff and revenue data

Unlock with Pro
Routes
ORAL
Dosage Forms
SOLUTION

Companies

Active Ingredient: DESMOPRESSIN ACETATE

DESMODA Approval History

Original
New Indication
New Form
Label Update
1 FDA actions from 2026 to 2026
Feb 2026 ORIGINAL
New Form · Type 3 - New Dosage Form

What DESMODA Treats

1 FDA approvals

Originally approved for its first indication in 2026 .

  • Other (1)
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

DESMODA FDA Label Details

Indications & Usage

FDA Label (PDF)

DESMODA is indicated for the management of central diabetes insipidus as antidiuretic replacement therapy for adults and pediatric patients. Limitations of Use • DESMODA is not indicated for the treatment of nephrogenic diabetes insipidus. DESMODA is a vasopressin analog indicated for the management of central diabetes insipidus as antidiuretic replacement therapy for adults and pediatric patients. Limitations of Use • DESMODA is not indicated for the treatment of nephrogenic diabetes insipidus.

DESMODA Patents & Exclusivity

Latest Patent: Apr 2044

Patents (2 active)

US12343372 Expires Apr 3, 2044
US12214010 Expires Apr 3, 2044
Source: FDA Orange Book

Pro Intelligence Preview

Deep insights for DESMODA

Revenue Insights

  • Quarterly revenue tracking
  • Historical trend analysis

Patent Timeline

  • Cliff: 2044
  • 2 active patents

Trial Analysis

  • Clinical trial tracking
  • Development stage analysis

Competitive Landscape

  • Competitor tracking
  • Same target/indication analysis
Unlock Full Intelligence

Full approval history • All patents • Revenue trends • Competitor analysis

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.